A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...
The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the ...
Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...
Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals VRTX revealed 10 unusual trades. Delving into the ...
Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and a $480.00 price target from Cantor Fitzgerald analyst Olivia Brayer ...
Vertex Pharmaceuticals (VRTX) ended the recent trading session at $470.37, demonstrating a +1.88% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily ...
JOSEPH PREZIOSO / AFP via Getty Images Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration. The drugmaker said the twice-daily pill, Journavx ...
Shares of Vertex Pharmaceuticals VRTX5.31%increase; green up pointing triangle rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug Administration approval.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback